Guardant health stock price

What is the upside for Guardant Health's stock? His predictions range from $ to $. On average, they expect Guardant Healths' stock price to hit $100 over the next 12 months. This indicates a possible rise in the current share price. View price targets from analysts at Guardant Health or top stocks from Wall Street analysts.

What are analysts'price targets for Guardant Health's stock?

11 Equity Research analysts have released annual target prices for Guardant Health stock. Your forecast varies between $ and $. On average, they expect Guardant Healths' stock price to hit $100 over the next 12 months.

Who owns Guardant Health stock?

Company members who own shares in Guardant Health include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A. Bertocci, Helmi Eltukhi, Ian T. Clark, Michael J. Wylie, Samir Kaul, Stanley J. Meresman and Stanley J. Meresmann. View Guardian Health Institutional Ownership Trends. Who are the main investors selling Guardant Health shares?

When is Guardant Health's next earnings release?

When is the next Guardian Health sale date? Guardant Health plans to release its next quarterly report on Wednesday, February 23, 2022. View Guardian Health's revenue forecast.

What is Guardant Health's (GHC) stock price potential upside?

His predictions range from $ to $. On average, they expect Guardant Healths' stock price to hit $100 over the next 12 months. This indicates a possible rise in the current share price.

Are Guardant Health's earnings expected to grow in the next year?

Guardant Health's earnings are expected to rise from ($) to ($) per share next year. Guardant Health's P/E ratio is , which means earnings are negative and cannot be compared to companies with positive earnings.

How did Guardant Health's sales beat Wall Street's Q3 estimates?

Guardant Health Inc (NASDAQ:GH) had third-quarter revenue of $3 million, up 27% year over year, better than Wall Street's estimate of $3 million. Guards Precision Oncology revenue increased 31% to $79 in the third quarter.

What is the upside for guardant health' s stock quote

Analyst Report: Guardian Health, Inc. Headquartered in Redwood City, California, Guardant Health offers blood and cancer testing for clinical and research use, and has research collaborations with major biopharmaceutical companies.

Is guardant’s target market trending?

Guardant is cautiously targeting oncology submarkets that are likely to face less competition, such as: B. Residual disease and treatment options. Market valuations for Guardant may be conservative if liquid biopsy rollout progresses faster than expected.

Why do hedge funds keep piling into Guardant Health?

Hedge funds continue to pile on Guardant Health, Inc. (GH) Investing in small cap stocks has always been a way to outperform the market, as small caps tend to grow faster than blue chip companies. This superiority comes at a price, however, as there are sometimes periods of heightened volatility.

What is guardant’s pipeline?

The company's portfolio includes Guardant Reveal (formerly Lunar1) to detect cancer recurrence in survivors and Lunar2, a liquid biopsy for early detection of cancer in high-risk individuals, with an initial focus on colorectal cancer. In addition, Guardant offers research development services.

Is Guardant Health girding for an antitrust fight?

These are anti-cartel belts. Guardian Health Inc. is a precision oncology company dedicated to treating cancer with its own blood tests, big data sets and advanced analytics. Decisions include choice of treatment, detection of recurrence, and early detection.

What is the upside for guardant health' s stock analysis

In the past three months, three Wall Street analysts have posted a 12-month price target for GH. Guardant Health's average price target is $175, suggesting upside potential. The analyst consensus on the rating is a strong buy rating based on three buy ratings.

What is the 12-month stock price forecast for Guardant Health?

The expected 12-month share price is , an increase from the last price. CITY OF REDWOOD, (BUSINESS WIRE) Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, today announced that the company will attend its upcoming 40th annual meeting.

What is the price targets for GH stock?

The high target price for GH is $ and the low target price for GH is $. There are currently 6 buy prices for a stock that result in a corresponding buy price.

What does guardguardant health do?

Guardian Health Inc. is a precision oncology company dedicated to treating cancer with its own blood tests, big data sets and advanced analytics. Decisions include choice of treatment, detection of recurrence, and early detection.

What are analysts' price targets for guardant health' s stock 2018

Based on ratings provided by 9 analysts last year, the consensus rating for Guardant Health stock is Buy, based on a current rating of 1 Hold and 8 Buy ratings for GH. Guardant Health's 12-month average price target is $ with a high $ target and a low $ target.

What is the price of the Guardant Health share price?

Today at 04:42 UTC, Guardant Health shares are trading at $. This heading information is delayed by 15 minutes. How has Guardant Health's share price changed this year?

What is guardguardant health?

Guardian Health Inc. is a precision oncology company. The company focuses on fighting cancer through blood tests, datasets and advanced analytics. The company has developed Guardant360, Guardant360 CDx and GuardantOMNI-based liquid biopsy tests for the diagnosis of advanced cancers.

What is the difference between guardant360 CDX and guardantomni tests?

The Guardant360 CDx test is a fluid-based biopsy that measures 55 genes associated with cancer. Their GuardantOMNI test has a larger panel of 500 genes, each of which looks for deoxyribonucleic acid (DNA) from a tumor circulating in the blood.

What are the earnings results for guardguardant Health (GH)?

Guardian Health Inc. (NASDAQ:GH) released its quarterly earnings on Thursday, Nov. The company reported earnings per share (EPS) of ($) for the quarter, excluding analyst estimates of ($) to $.

What are analysts' price targets for guardant health' s stock 2020

Guardant Health's 12-month average price target is $ with a high $ target and a low $ target. Learn more Do Wall Street analysts think Guardant Health outperforms its competitors? Analysts like Guardant Health own more shares than other healthcare companies.

How did guardguardant Health's (GH) Q4 earnings compare to analysts'estimates?

Guardian Health Inc. (NASDAQ:GH) released its quarterly earnings on Thursday, Nov. The company reported ($) earnings per share (EPS) for the quarter, below the analyst consensus estimate of ($)$. The company made millions of dollars in the quarter, compared to analysts' expectations of millions of dollars.

Who owns guardant health stock price

Daiwa Securities Group Inc. currently owns 347 shares of the company worth $43,000, having bought an additional 148 shares in the past quarter. the stake is currently held by institutional investors. Also on Tuesday, November 23, CEO Helmi Eltuhi bought 54,500 shares of Guardant Health.

Does guardant offer research development services?

In addition, Guardant offers research development services. The United States accounts for 90% of total sales, while other markets account for the remaining 10%.

Who owns guardant health stock news

Black Rock Inc increased its shares of Guardant Health in the second quarter. black rock incl. he currently owns 5,525,679 shares of the company worth $686,235,000 after purchasing an additional 121,224 shares last quarter.

Will NeoGenomics acquire Guardant Health?

Shares of healthcare company Guardant Health (NASDAQ:GH) fell this afternoon after unconfirmed reports that it is interested in acquiring indirect competitor NeoGenomics (NASDAQ:NEO).

What is guardant 360?

The company offers Guardant 360, a blood test (liquid biopsy) for advanced cancer treatment options, and Guardant Omni, a broader gene panel for immuno-oncology research.

Who owns guardant health stock predictions

Motley Fool owns and recommends Guardant Health and Illumina. Motley Fool has a disclosure policy.

How do I contact guardguardant health?

Guardian Health Inc. 505 Penobscot Dr. Redwood City, CA 94063 Phone: .

Who owns guardant health stock review

Jason Hawthorne owns shares of Guardant Health. The Motley Fool owns and recommends shares in Guardant Health. The Motley Fool recommends The Exact Sciences.

Is Guardant Health a better buy than Illumina?

There are several companies in this area that have generated significant revenue, including Illumina and Guardant Health. Illumina is a pioneer in the genetic sequencing market and Guardant is a rising star in the liquid biopsy field. Which of these healthcare stocks are the best long-term buys?

What is guardant’s market opportunity?

Guardant's Therapeutic Choice products have a clinical and biopharmaceutical market potential of approximately $6 billion. The company has other exciting products in development, including a moon test, which is currently only available for research purposes. There are two lunar programs: Lunar1 and Lunar2.

Who owns guardguardant health stock?

Guardant Health shares are held by a number of retail and institutional investors. The main institutional investors are Morgan Stanley , BlackRock Inc. , Capital Research Global Investors , Viking Global Investors LP , Coatue Management LLC and Credit Suisse AG .

How much does guardguardant health make a year?

Guardant Health has a market cap in the billions of dollars and annual sales in the millions of dollars. The company earns millions of dollars each year in net income (earnings) or ($) based on earnings per share.

Who holds Guardant Health's stock?

Insiders only own shares in Guardian Health. Guardant Health's stock is located in institutions. High institutional ownership can be a sign of strong market confidence in this company.

What does Guardant Health do?

Subscribe to Premium to see how precision oncology company Guardant Health, Inc. blood tests, datasets and analysis in the US and around the world.